Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?
A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.
EP: 1.Current Strategies in Diagnosis and Classification of Small Cell Lung Cancer
EP: 2.Small Cell Lung Cancer: What is the Role of Biomarker Testing?
EP: 3.Real-World Data and Observed AEs With Frontline Chemo IO Therapy in SCLC
EP: 4.Novel and Emerging Frontline Treatment Strategies in SCLC
EP: 5.Overview of Frontline Treatment Options in Small Cell Lung Cancer
EP: 6.Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?
EP: 7.Overview of Second-Line Treatment Options in SCLC
EP: 8.Clinical Data With Lurbinectedin in Small Cell Lung Cancer
EP: 9.The Evolving Treatment Landscape of Small Cell Lung Cancer
Transcript:
Christian Grohé, MD:What do you think is the role of immunotherapy in the first-line setting? Is that used most in extensive or mostly use of limited-stage disease?
Laurent Greiller, MD:We can say that extensive-stage small cell lung cancer patient immunotherapy is a standard combination with chemotherapy platinum receptor. We have the data from the CASPIAN trial ((NCT03043872), and from the IMPOWER133 trial (NCT02763579). For patients with limited-stage small cell lung cancer, IO is not a standard because the STIMULI trial (NCT02046733) assessed the role of maintenance therapy after chemoradiotherapy in patients with limited-stage small cell lung cancer. The IO tested in this trial was a combination of [nivolumab ipilimumab] and this randomized phase 2 trial was negative. Today, there are a number of ongoing trials assessing the addition of immunotherapy to the standard radiochemotherapy. The results of these trials are still pending. So, for limited-stage small cell lung cancer, IO is not a standard at least today.
Transcript edited for clarity.
